PEGASYS(R) hepatitis C therapy approved in the United States for monotherapy
Hoffmann-La Roche Limited today announced that the U.S. Food and Drug Administration (FDA) has approved PEGASYS(R) (peginterferon alfa-2a) for the treatment of adults with chronic
